Document is current
Any future updates will be listed below
-
Authors
Chiba, Shiho
Kiso, Maki
Yamada, Shinya
Someya, Kazuhiko
Onodera, Yoshikuni
Yamaguchi, Aya
Matsunaga, Satoko
Uraki, Ryuta https://orcid.org/0000-0003-0890-1922
Iwatsuki-Horimoto, Kiyoko https://orcid.org/0000-0002-8266-020X
Yamayoshi, Seiya https://orcid.org/0000-0001-7768-5157
Takeshita, Fumihiko
Kawaoka, Yoshihiro https://orcid.org/0000-0001-5061-8296
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP243fa827010, JP243fa827010)
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 2 October 2024
First Online: 14 October 2024
Competing interests
: S.Y., K.S., Y.O., A.Y., T.M., and F.T. are employees of Daiichi Sankyo Co., Ltd. Y.K. has received unrelated funding support from FUJIFILM Toyama Chemical Co., Ltd.; TAUNS Laboratories, Inc.; Shionogi & Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; KM Biologics Co., Ltd.; Kyoritsu Seiyaku Corporation; Shinwa Corporation; and Fujirebio Diagnostics. Y.K. is also a co-founder of FluGen, Inc. Y.K. is supported by grants from the Japan Program for Infectious Diseases Research and Infrastructure (JP24wm0125002) and the Japan Initiative for World-leading Vaccine Research and Development Centers (JP243fa627001) from Japan Agency for Medical Research and Development (AMED). Y.K. and Daiichi Sankyo Co., Ltd. are also supported by the Program on R&D of new generation vaccine including new modality application (JP243fa827010) from AMED. All other authors declare no competing interests.
